PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1373
- Registration Number
- NCT00808015
- Locations
- ๐ต๐ญ
Pfizer Investigational Site, Quezon City, Philippines
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
Phase 3
Completed
- Conditions
- OsteoporosisMenopause
- Interventions
- Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mgDrug: Placebo
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1886
- Registration Number
- NCT00808132
- Locations
- ๐ต๐ฑ
Pfizer Investigational Site, Wroclaw, Poland
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
Phase 2
Completed
- Conditions
- Lung DiseasesPulmonary Disease, Chronic ObstructiveLung Diseases, Obstructive
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 405
- Registration Number
- NCT00808288
- Locations
- ๐น๐ท
Pfizer Investigational Site, Izmir, Turkey
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents
Phase 2
Completed
- Conditions
- Meningitis, Meningococcal
- Interventions
- Other: normal saline (placebo)Biological: meningococcal B rLP2086 vaccine.
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 538
- Registration Number
- NCT00808028
- Locations
- ๐ต๐ฑ
ZOZ w Debicy, Poradnia Chorob Zakaznych, Debica, Poland
๐ต๐ฑSP ZOZ Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie, Krakow, Poland
๐ต๐ฑNZOZ Salmed, Leczna, Poland
Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT00807118
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
Phase 3
Terminated
- Conditions
- FungemiaNeutropeniaCandidiasis
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00806351
- Locations
- ๐ธ๐ฐ
Pfizer Investigational Site, Kosice, Slovakia
UK Study Assessing Flexible Dose Fesoterodine in Adults
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 331
- Registration Number
- NCT00806494
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Swindon, United Kingdom
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
Phase 3
Terminated
- Conditions
- CandidiasisFungemia
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00805740
- Locations
- ๐จ๐ญ
Pfizer Investigational Site, Geneve 14, Switzerland
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxisยฎ IV
Completed
- Conditions
- CandidemiaOther Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 244
- Registration Number
- NCT00802854
- Locations
- ๐ฐ๐ท
Dong-A University Hospital, Busan, Korea, Republic of
๐ฐ๐ทDong-A University Medical Center (Dong-A University Hospital), Busen, Korea, Republic of
๐ฐ๐ทKeimyung University Dongsan Medical Center (KUDMC), Daegu, Korea, Republic of
Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C]-esreboxetine
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT00800956
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Tacoma, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath